Table 1 The Comparison of clinical characteristics in patients and controls

Age, years

44.6 ± 10.4

44.8 ± 9.5

0.718

Men, n (%)

19 (63.3%)

19 (63.3%)

PD time, months

–

11 (3–18)

BMI, kg/m²

22.35 ± 2.39

22.94 ± 2.72

0.353

BSA, m²

1.655 (1.527,1.870)^a

1.663 (1.501,1.763)

0.371

SBP, mmHg

119.6 ± 12.60

135.1 ± 26.31

0.008

DBP, mmHg

74.8 ± 7.87

84.2 ± 11.34

0.002

CREA, umol/L

60.6 ± 12.25

937.2 ± 318.33

< 0.001

BUN, mmol/L

4.9 ± 1.16

20.0 ± 6.94

< 0.001

Ca, mmol/L

2.22 ± 0.13

2.18 ± 0.22

0.445

P, mmol/L

1.11 ± 0.23

1.76 ± 0.58

< 0.001

Hb, g/L

135 ± 15.0

108 ± 13.8

< 0.001

 Glomerulonephritis

17 (56.6%)

 Diabetic nephropathy

3 (10%)

 Hypertensive nephrosclerosis

5 (16.7%)

 Polycystic kidney

2 (6.7%)

 Nephrotic syndrome

1 (3.3%)

 Unknown

2 (6.7%)

 Diuretics

18 (60%)

 RAAS blockers

15 (50%)

 Ca²⁺ channel blockers

23 (76.7%)

 α-Receptor blockers

19 (63.3%)

 β-Receptor blockers

15 (50%)